ERBB2 and neoplasm: The results showed that the clinicopathological factors of molecular subtypes, The American Joint Committee on Cancer (AJCC) stage, tumor size, ER status, PR status, and HER2 status were significantly correlated with all the immune/stromal/ESTIMATE scores in invasive BRCA (p < 0.05, Table 1).